Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.
Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.
Transcript
What do you believe will be the next breakthroughs in cardiovascular medicine?
Well there will be a trial presented at this meeting; the topline results have been announced in a press release. It's the use of a pure anti-inflammatory drug, known as canakinumab, and the trial is CANTOS. It's going to be presented by Paul Ridker, MD. Since the data are still embargoed, what I can say here is that the topline results are that the trial met its pre-specificed endpoints.
But watch this space. Because here is a drug that doesn't lower low-density lipoprotein cholesterol, doesn't raise high-density lipoprotein, doesn't loewr triglycerides, but based upon the press release, it reduces major cardiovascular events. A pure anti-inflammatory strategy. It's fascinating. It's a new window opening on another approach to treatment. And we're very excited about the results.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More